Havas Health Network is set to expand its presence in the rapidly growing GLP-1 treatment market with the launch of its European consultancy. The initiative will be introduced at a flagship event, “Shape Shifting: A Close Look at the Health and Wellness Disruptor – GLP-1,” taking place on 13 March at the Havas Village in Paris.
The event will bring together branding experts, thought leaders, and healthcare professionals to explore the transformative impact of GLP-1 medications, which are reshaping the health and wellness landscape beyond their initial applications in diabetes and weight loss.
Havas Health Network aims to provide clients, industry partners, and brand marketers with strategic insights to navigate this evolving sector. Inspired by the success of its GLP101 Day event in New York last November, the company now seeks to address the specific challenges and opportunities within the European market.
GLP-1 treatments have gained significant traction in North America, disrupting healthcare, consumer goods, and lifestyle industries. With the global market projected to reach $5.56 billion (£4.4 billion) by 2030, Havas sees Europe as a key region for innovation and market expansion.
Chloé Depiesse, Managing Director at Havas Health Network, emphasised the importance of tailoring strategies to local contexts: “The North American and European markets, while similar, have unique cultural nuances that will impact treatment adoption and engagement beyond healthcare.”
Anna Maria Marra, CEO of Havas Health Network Europe, highlighted the company’s commitment to staying at the forefront of industry trends: “With our strong network and understanding of the evolving GLP-1 space, we are committed to delivering innovative solutions that meet the emerging demands of the European market.”
The consultancy will support brands in understanding the shifting dynamics of the GLP-1 sector, offering guidance on market entry, branding, and consumer engagement.
For further details on Havas Health Network’s GLP-1 consultancy and access to its proprietary GLP-1 Prosumer Report, visit the company’s website.
